< -5%

-5% to -3%

Omax Autos

-3% to 0%

0% to 3%

Rasandik Engg

Autoline Ind

Jay BharatMarut

3% to 5%

IRB Infrastructure share price will remain in focus on November 17 following the company received a project of Rs 9270 crore from National Highways Authority of India (NHAI) .

IRB Infrastructure Trust, the private InvIT of IRB Infrastructure Developers has received the Letter of Award (LoA) from the National Highways Authority of India (NHAI) for the TOT-17 bundle covering 366Kms of Lucknow-Ayodhya-Gorakhpur Corridor on NH-27 and part of Lucknow-Varanasi Corridor on NH-731, for a revenue linked concession period of 20 years.

Post TOT-17 project to IRB Group’s project portfolio (including Private and Public InvIT) will have 27 highway projects that include 18 BOT, 5 TOT, and 4 HAM projects.

<a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-updates-gift-nifty-indicates-a-firm-opening-us-asian-markets-mixed-liveblog-13679241.html">Catch all the market action on our live blog</a>

The company had collected toll of Rs 556.7 crore for the month of September, marking an 11% increase from Rs 501.8 crore in the same month last year.

The company's standalone net profit jumped 17.8% to Rs 188.37 crore in September 2025 against Rs 159.89 crore in September 2024.

The revenue of the company's rose 7 percent at Rs 1,064.72 crore versus Rs 993.75 crore, YoY.

In the previous trading session, the share closed at Rs 42.91, up Rs 0.56, or 1.32 percent.

The share touched a 52-week high of Rs 61.98 and a 52-week low of Rs 40.54 on 10 December, 2024 and 26 September, 2025, respectively.

Currently, the stock is trading 30.77 percent below its 52-week high and 5.85 percent above its 52-week low.

The market capitalisation of the company stands at Rs 25,913.35 crore.

Ownership, Material Conflicts of Interest and Disciplinary History

MCD is a wholly owned subsidiary of Network 18 Media & Investments Ltd ("Network18"), in which Independent Media Trust (IMT) holds 56.89% stake. Reliance Industries Limited ("RIL") is the sole beneficiary of IMT. Network18 and RIL and their subsidiaries, joint ventures and associates can be considered as associates of MCD.

Details of Associate

Receipt of Compensation

Third-Party Compensation

Employment History

Market-Making Activities

Use of Artificial Intelligence

IRB Infrastructure share price in focus after arm bags project of Rs 9,270 crore

IRB Infrastructure share price will remain in focus on November 17 following the company received a project of Rs 9270 crore from National Highways Authority of India (NHAI) .

IRB Infrastructure Trust, the private InvIT of IRB Infrastructure Developers has received the Letter of Award (LoA) from the National Highways Authority of India (NHAI) for the TOT-17 bundle covering 366Kms of Lucknow-Ayodhya-Gorakhpur Corridor on NH-27 and part of Lucknow-Varanasi Corridor on NH-731, for a revenue linked concession period of 20 years.

Post TOT-17 project to IRB Group’s project portfolio (including Private and Public InvIT) will have 27 highway projects that include 18 BOT, 5 TOT, and 4 HAM projects.

Catch all the market action on our live blog

The company had collected toll of Rs 556.7 crore for the month of September, marking an 11% increase from Rs 501.8 crore in the same month last year.

The company's standalone net profit jumped 17.8% to Rs 188.37 crore in September 2025 against Rs 159.89 crore in September 2024.

The revenue of the company's rose 7 percent at Rs 1,064.72 crore versus Rs 993.75 crore, YoY.

In the previous trading session, the share closed at Rs 42.91, up Rs 0.56, or 1.32 percent.

The share touched a 52-week high of Rs 61.98 and a 52-week low of Rs 40.54 on 10 December, 2024 and 26 September, 2025, respectively.

Currently, the stock is trading 30.77 percent below its 52-week high and 5.85 percent above its 52-week low.

The market capitalisation of the company stands at Rs 25,913.35 crore.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/alembicpharmaceuticals/AP35">Alembic Pharmaceuticals</a> share price will remain in focus on November 17 following the company received final approval from USFDA for angina drug.

".... has received final approval from the US Food &amp; Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg," company said in its press release.

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Cardizem Tablets, 30 mg, 60 mg, 90 mg, and 120 mg, of Bausch Health US, LLC.

Diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm, it added.

With this, the company has a cumulative total of 230 ANDA approvals (210 final approvals and 20 tentative approvals) from USFDA.

<a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-updates-gift-nifty-indicates-a-firm-opening-us-asian-markets-mixed-liveblog-13679241.html">Catch all the market action on our live blog</a>

On November 13, the company received final approval from the for its ANDA Dexlansoprazole Delayed-Release Capsules, 30 mg and 60 mg, which is therapeutically equivalent to the reference listed drug (RLD), Dexilant Delayed-Release Capsules, 30 mg and 60 mg, of Takeda Pharmaceuticals USA, Inc.

On November 7, the company received final USFDA approval for its ANDA Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, Single-Dose Autoinjector System.

Sumatriptan injection is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Refer label for a detailed indication.

In the previous trading session, the share closed at Rs 902.80, down Rs 14.50, or 1.58 percent.

The share touched a 52-week high of Rs 1,122.40 and a 52-week low of Rs 725.60 on 06 January, 2025 and 03 March, 2025, respectively.

Currently, the stock is trading 19.57 percent below its 52-week high and 24.42 percent above its 52-week low.

The market capitalisation of the company stands at Rs 17,745.72 crore.

Alembic Pharma shares in focus on USFDA nod for Diltiazem Hydrochloride tablets

Alembic Pharmaceuticals share price will remain in focus on November 17 following the company received final approval from USFDA for angina drug.

&quot;.... has received final approval from the US Food &amp;amp; Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg,&quot; company said in its press release.

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Cardizem Tablets, 30 mg, 60 mg, 90 mg, and 120 mg, of Bausch Health US, LLC.

Diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm, it added.

With this, the company has a cumulative total of 230 ANDA approvals (210 final approvals and 20 tentative approvals) from USFDA.

Catch all the market action on our live blog

On November 13, the company received final approval from the for its ANDA Dexlansoprazole Delayed-Release Capsules, 30 mg and 60 mg, which is therapeutically equivalent to the reference listed drug (RLD), Dexilant Delayed-Release Capsules, 30 mg and 60 mg, of Takeda Pharmaceuticals USA, Inc.

On November 7, the company received final USFDA approval for its ANDA Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, Single-Dose Autoinjector System.

Sumatriptan injection is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Refer label for a detailed indication.

In the previous trading session, the share closed at Rs 902.80, down Rs 14.50, or 1.58 percent.

The share touched a 52-week high of Rs 1,122.40 and a 52-week low of Rs 725.60 on 06 January, 2025 and 03 March, 2025, respectively.

Currently, the stock is trading 19.57 percent below its 52-week high and 24.42 percent above its 52-week low.

The market capitalisation of the company stands at Rs 17,745.72 crore.

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, order wins, and appointments, here’s a quick look at which stocks will be in focus in today's trade:

<a href="https://www.moneycontrol.com/markets/earnings/" target="_blank">Quarterly Earnings</a>

<a href="https://www.moneycontrol.com/india/stockpricequote/hospitalhealthcare-services/maxhealthcareinstitute/MHI" target="_blank">Max Healthcare Institute</a> Q2 (Consolidated YoY)

Profit zooms 74.3% to Rs 491.3 crore Vs Rs 281.8 crore

Revenue grows 25% to Rs 2,135.5 crore Vs Rs 1,707.5 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/retail/v2retail/VR02" target="_blank">V2 Retail</a> Q2 (Consolidated YoY)

Profit stands at Rs 17.23 crore Vs loss of Rs 1.93 crore

Revenue surges 86.5% to Rs 708.6 crore Vs Rs 380 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/hospitalsmedical-services/narayanahrudayalaya/NH" target="_blank">Narayana Hrudayala</a> Q2 (Consolidated YoY)

Profit spikes 29.6% to Rs 258.3 crore Vs Rs 199.3 crore

Revenue increases 20.3% to Rs 1,643.8 crore Vs Rs 1,366.7 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/power-generationdistribution/gmrpowerurbaninfra/GPU" target="_blank">GMR Power and Urban Infra</a> Q2 (Consolidated YoY)

Profit zooms 248.2% to Rs 888.4 crore Vs Rs 255.1 crore

Revenue soars 30.8% to Rs 1,810.4 crore Vs Rs 1,383.8 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/constructioncontracting-civil/ashokabuildcon/AB" target="_blank">Ashoka Buildcon</a> Q2 (Consolidated YoY)

Profit sinks 82.9% to Rs 78 crore Vs Rs 457 crore

Revenue drops 25.6% to Rs 1,851.2 crore Vs Rs 2,488.9 crore

Exceptional loss at Rs 219.3 crore Vs Nil

Stocks to Watch

<a href="https://www.moneycontrol.com/india/stockpricequote/electric-equipment/websolenergysystem/WSL" target="_blank">Websol Energy System</a>

The solar cells and modules manufacturer, through its subsidiary Websol Renewables, has entered into a Memorandum of Understanding (MoU) with the Andhra Pradesh Economic Development Board (APEDB) for the development of a 4 GW integrated solar cell and module manufacturing facility in Andhra Pradesh.

<a href="https://www.moneycontrol.com/india/stockpricequote/diversified/trualtbioenergy/TBL01" target="_blank">TruAlt Bioenergy</a>

The biofuels producer has signed a Memorandum of Understanding (MoU) with the Andhra Pradesh Economic Development Board (APEDB) to develop one of the world’s largest Sustainable Aviation Fuel (SAF) production facilities in Andhra Pradesh. Under the MoU, TruAlt will invest approximately Rs 2,250 crore to establish an integrated ethanol-to-SAF manufacturing facility.

<a href="https://www.moneycontrol.com/india/stockpricequote/transport-infrastructure/irbinfrastructuredevelopers/IID01" target="_blank">IRB Infrastructure Developers</a>

IRB Infrastructure Trust, the Private InvIT sponsored by IRB Infrastructure Developers, has received the Letter of Award (LoA) from the National Highways Authority of India (NHAI) for the TOT-17 Bundle, covering 366 km of the Lucknow–Ayodhya–Gorakhpur Corridor on NH-27 and part of the Lucknow–Varanasi Corridor on NH-731 in Uttar Pradesh, for a revenue-linked concession period of 20 years.

The Trust will pay an upfront bid concession fee of Rs 9,270 crore to NHAI for the revenue-linked concession period of 20 years.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/alembicpharmaceuticals/AP35" target="_blank">Alembic Pharmaceuticals</a>

The company has received final approval from the US Food &amp; Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride tablets.

Diltiazem Hydrochloride tablets are indicated for the management of chronic stable angina.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/lupin/L" target="_blank">Lupin</a>

The United States Food and Drug Administration (USFDA) has completed a product-specific Pre-Approval Inspection at the company’s Unit-1 oral solid dosage manufacturing facility in Nagpur. The inspection was carried out from November 10 to 14 and concluded with zero 483 observations.

<a href="https://www.moneycontrol.com/india/stockpricequote/banks-private-sector/karnatakabank/KB04" target="_blank">Karnataka Bank</a>

The bank has appointed Raghavendra S Bhat as the new Managing Director &amp; CEO, effective November 16, for a period of one year.

<a href="https://www.moneycontrol.com/india/stockpricequote/auto-carsjeeps/marutisuzukiindia/MS24" target="_blank">Maruti Suzuki India</a>

The leading carmaker has announced a recall of 39,506 units of the Grand Vitara, manufactured from December 9, 2024, to April 29, 2025. It is suspected that the fuel level indicator and warning light in the speedometer assembly (Part) in some of these vehicles may not accurately reflect the fuel status as intended.

<a href="https://www.moneycontrol.com/india/stockpricequote/auto-ancillaries-brakes/olaelectricmobility/OEM" target="_blank">Ola Electric Mobility</a>

The company has commenced test rides of its 4680 Bharat Cell–powered vehicles at its flagship stores across India. The S1 Pro+ (5.2 kWh) is the first product to be powered by the company’s indigenously manufactured 4680 Bharat Cell battery pack.

Bulk Deals

<a href="https://www.moneycontrol.com/india/stockpricequote/miscellaneous/sagility/SIL27" target="_blank">Sagility</a>

Netherlands-based promoter Sagility B V sold 76.9 crore equity shares (equivalent to 16.4% of paid-up equity) in Sagility at Rs 47.6 per share, valued at Rs 3,660.44 crore.

As of September 2025, promoter held 67.38% stake in Sagility, which now reduced to around 51%.

However, global and domestic institutional investors were buyers for some portion of the stake sold by promoter at same price in Sagility. Portfolio management company Unifi Capital and its Unifi Blend Fund 2 were the largest buyer amongst them, acquiring 22.05 crore shares (4.71% stake) at same price, valued at Rs 1,049.65 crore.

ICICI Prudential Mutual Fund bought 3.13 crore shares in Sagility for Rs 149.39 crore, while Societe Generale picked up 8.48 crore shares for Rs 403.75 crore.

Further, Norges Bank on account of the Government Pension Fund Global purchased 3.71 crore shares amounting to Rs 176.59 crore, and Morgan Stanley Asia Singapore acquired 2.76 crore shares for Rs 131.47 crore.

Block Deals

<a href="https://www.moneycontrol.com/india/stockpricequote/cement-major/rainindustries/RC12" target="_blank">Rain Industries</a>

First Water Fund, owned by First Water Capital Advisors, bought additional 26 lakh shares (0.77% stake) in the calcined petroleum coke, coal tar pitch and other specialty chemicals producer at Rs 120 per share for Rs 31.2 crore.

Haresh Tikamdas Kaswani, and K2 Family Private Trust were the sellers in this block deal, offloading 12 lakh shares for Rs 14.4 crore and 14 lakh shares for Rs 16.8 crore, respectively, in Rain Industries.

<a href="https://www.moneycontrol.com/india/stockpricequote/trading/shailyengineeringplastics/SEP02" target="_blank">Shaily Engineering Plastics</a>

Promoters - Amit Mahendra Sanghvi, and Laxman Sanghvi sold 1.5 lakh shares (0.32 percent stake) at Rs 2,585.1 per share for Rs 38.77 crore.

Morgan Stanley IFSC Fund, SI Investments Broking, and Motilal Oswal MF picked the said 0.32 percent stake in Shaily from promoters.

<a href="https://www.moneycontrol.com/india/stockpricequote/finance-others/pinelabs/PLL01" target="_blank">Pine Labs</a>

Morgan Stanley Asia (Singapore) picked up 14.09 lakh shares (0.1 percent stake) in the fintech company at Rs 257.5 per share for Rs 36.28 crore from UBS AG.

Stocks Trade Ex-Dividend

Arfin India
Balrampur Chini Mills
EPL
GMM Pfaudler
Gopal Snacks
HB Portfolio
Pearl Global Industries
Surya Roshni

Stocks Trade Ex-Date for Rights

Adani Enterprises
Baid Finserv

Stock Trades Ex-Date for Income Distribution (InvIT)

Altius Telecom Infrastructure Trust

Stock in F&amp;O ban

SAIL

Stocks to Watch Today: Lupin, Narayana Hrudayala, V2 Retail, Websol, TruAlt Bioenergy, IRB Infra, Alembic Pharma, Max Healthcare in focus on 17 November

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, order wins, and appointments, here’s a quick look at which stocks will be in focus in today's trade:

Quarterly Earnings

Max Healthcare Institute Q2 (Consolidated YoY)

Profit zooms 74.3% to Rs 491.3 crore Vs Rs 281.8 crore

Revenue grows 25% to Rs 2,135.5 crore Vs Rs 1,707.5 crore

V2 Retail Q2 (Consolidated YoY)

Profit stands at Rs 17.23 crore Vs loss of Rs 1.93 crore

Revenue surges 86.5% to Rs 708.6 crore Vs Rs 380 crore

Narayana Hrudayala Q2 (Consolidated YoY)

Profit spikes 29.6% to Rs 258.3 crore Vs Rs 199.3 crore

Revenue increases 20.3% to Rs 1,643.8 crore Vs Rs 1,366.7 crore

GMR Power and Urban Infra Q2 (Consolidated YoY)

Profit zooms 248.2% to Rs 888.4 crore Vs Rs 255.1 crore

Revenue soars 30.8% to Rs 1,810.4 crore Vs Rs 1,383.8 crore

Ashoka Buildcon Q2 (Consolidated YoY)

Profit sinks 82.9% to Rs 78 crore Vs Rs 457 crore

Revenue drops 25.6% to Rs 1,851.2 crore Vs Rs 2,488.9 crore

Exceptional loss at Rs 219.3 crore Vs Nil

Stocks to Watch

Websol Energy System

The solar cells and modules manufacturer, through its subsidiary Websol Renewables, has entered into a Memorandum of Understanding (MoU) with the Andhra Pradesh Economic Development Board (APEDB) for the development of a 4 GW integrated solar cell and module manufacturing facility in Andhra Pradesh.

TruAlt Bioenergy

The biofuels producer has signed a Memorandum of Understanding (MoU) with the Andhra Pradesh Economic Development Board (APEDB) to develop one of the world’s largest Sustainable Aviation Fuel (SAF) production facilities in Andhra Pradesh. Under the MoU, TruAlt will invest approximately Rs 2,250 crore to establish an integrated ethanol-to-SAF manufacturing facility.

IRB Infrastructure Developers

IRB Infrastructure Trust, the Private InvIT sponsored by IRB Infrastructure Developers, has received the Letter of Award (LoA) from the National Highways Authority of India (NHAI) for the TOT-17 Bundle, covering 366 km of the Lucknow–Ayodhya–Gorakhpur Corridor on NH-27 and part of the Lucknow–Varanasi Corridor on NH-731 in Uttar Pradesh, for a revenue-linked concession period of 20 years.

The Trust will pay an upfront bid concession fee of Rs 9,270 crore to NHAI for the revenue-linked concession period of 20 years.

Alembic Pharmaceuticals

The company has received final approval from the US Food &amp;amp; Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride tablets.

Diltiazem Hydrochloride tablets are indicated for the management of chronic stable angina.

Lupin

The United States Food and Drug Administration (USFDA) has completed a product-specific Pre-Approval Inspection at the company’s Unit-1 oral solid dosage manufacturing facility in Nagpur. The inspection was carried out from November 10 to 14 and concluded with zero 483 observations.

Karnataka Bank

The bank has appointed Raghavendra S Bhat as the new Managing Director &amp;amp; CEO, effective November 16, for a period of one year.

Maruti Suzuki India

The leading carmaker has announced a recall of 39,506 units of the Grand Vitara, manufactured from December 9, 2024, to April 29, 2025. It is suspected that the fuel level indicator and warning light in the speedometer assembly (Part) in some of these vehicles may not accurately reflect the fuel status as intended.

Ola Electric Mobility

The company has commenced test rides of its 4680 Bharat Cell–powered vehicles at its flagship stores across India. The S1 Pro+ (5.2 kWh) is the first product to be powered by the company’s indigenously manufactured 4680 Bharat Cell battery pack.

Bulk Deals

Sagility

Netherlands-based promoter Sagility B V sold 76.9 crore equity shares (equivalent to 16.4% of paid-up equity) in Sagility at Rs 47.6 per share, valued at Rs 3,660.44 crore.

As of September 2025, promoter held 67.38% stake in Sagility, which now reduced to around 51%.

However, global and domestic institutional investors were buyers for some portion of the stake sold by promoter at same price in Sagility. Portfolio management company Unifi Capital and its Unifi Blend Fund 2 were the largest buyer amongst them, acquiring 22.05 crore shares (4.71% stake) at same price, valued at Rs 1,049.65 crore.

ICICI Prudential Mutual Fund bought 3.13 crore shares in Sagility for Rs 149.39 crore, while Societe Generale picked up 8.48 crore shares for Rs 403.75 crore.

Further, Norges Bank on account of the Government Pension Fund Global purchased 3.71 crore shares amounting to Rs 176.59 crore, and Morgan Stanley Asia Singapore acquired 2.76 crore shares for Rs 131.47 crore.

Block Deals

Rain Industries

First Water Fund, owned by First Water Capital Advisors, bought additional 26 lakh shares (0.77% stake) in the calcined petroleum coke, coal tar pitch and other specialty chemicals producer at Rs 120 per share for Rs 31.2 crore.

Haresh Tikamdas Kaswani, and K2 Family Private Trust were the sellers in this block deal, offloading 12 lakh shares for Rs 14.4 crore and 14 lakh shares for Rs 16.8 crore, respectively, in Rain Industries.

Shaily Engineering Plastics

Promoters - Amit Mahendra Sanghvi, and Laxman Sanghvi sold 1.5 lakh shares (0.32 percent stake) at Rs 2,585.1 per share for Rs 38.77 crore.

Morgan Stanley IFSC Fund, SI Investments Broking, and Motilal Oswal MF picked the said 0.32 percent stake in Shaily from promoters.

Pine Labs

Morgan Stanley Asia (Singapore) picked up 14.09 lakh shares (0.1 percent stake) in the fintech company at Rs 257.5 per share for Rs 36.28 crore from UBS AG.

Stocks Trade Ex-Dividend

Arfin India
Balrampur Chini Mills
EPL
GMM Pfaudler
Gopal Snacks
HB Portfolio
Pearl Global Industries
Surya Roshni

Stocks Trade Ex-Date for Rights

Adani Enterprises
Baid Finserv

Stock Trades Ex-Date for Income Distribution (InvIT)

Altius Telecom Infrastructure Trust

Stock in F&amp;amp;O ban

SAIL

Netherlands-based promoter Sagility B V has offloaded 16.4 percent equity stake in Sagility that provides technology-enabled business solutions and services to clients in the US healthcare industry, via open market transactions on November 14.

Despite this big stake sale, <a href="https://www.moneycontrol.com/india/stockpricequote/miscellaneous/sagility/SIL27">Sagility</a> shares rallied 5.6 percent to Rs 53.28 with above-average volumes, witnessing a strong breakout after consolidation seen in the past couple of weeks.

Sagility B V sold 76.9 crore equity shares (equivalent to 16.4 percent of paid-up equity) at Rs 47.6 per share, valued at Rs 3,660.44 crore.

As of September 2025, promoter held 67.38 percent stake in Sagility, which now reduced to around 51 percent.

However, global and domestic institutional investors were buyers for some portion of the stake sold by promoter at same price in Sagility. Portfolio management company Unifi Capital and its Unifi Blend Fund 2 were the largest buyer amongst them, acquiring 22.05 crore shares (4.71 percent stake) at same price, valued at Rs 1,049.65 crore.

ICICI Prudential Mutual Fund bought 3.13 crore shares in Sagility for Rs 149.39 crore, while Societe Generale picked up 8.48 crore shares for Rs 403.75 crore.

Further, Norges Bank on account of the Government Pension Fund Global purchased 3.71 crore shares amounting to Rs 176.59 crore, and Morgan Stanley Asia Singapore acquired 2.76 crore shares for Rs 131.47 crore.

Meanwhile, <a href="https://www.moneycontrol.com/india/stockpricequote/cement-major/rainindustries/RC12">Rain Industries</a> was also in action, falling 2.44 percent to Rs 116.87, and extending downtrend for eighth consecutive session. First Water Fund, owned by First Water Capital Advisors, bought additional 26 lakh shares (0.77 percent stake) in the calcined petroleum coke, coal tar pitch and other specialty chemicals producer at Rs 120 per share for Rs 31.2 crore.

Haresh Tikamdas Kaswani, and K2 Family Private Trust were the sellers in this block deal, offloading 12 lakh shares for Rs 14.4 crore and 14 lakh shares for Rs 16.8 crore, respectively, in Rain Industries.

The brisk action was also seen in <a href="https://www.moneycontrol.com/india/stockpricequote/trading/shailyengineeringplastics/SEP02">Shaily Engineering Plastics</a>, the injection moulded precision plastic components maker, which ended at new closing high of Rs 2,622.8, up 0.47 percent. Promoters - Amit Mahendra Sanghvi, and Laxman Sanghvi sold 1.5 lakh shares (0.32 percent stake) at Rs 2,585.1 per share for Rs 38.77 crore.

Morgan Stanley IFSC Fund, SI Investments Broking, and Motilal Oswal MF picked the said 0.32 percent stake in Shaily from promoters.

The small block deal was also seen in <a href="https://www.moneycontrol.com/india/stockpricequote/finance-others/pinelabs/PLL01">Pine Labs</a>, the fintech company, which surged 13.52 percent to Rs 250.89 on its market debut today. Morgan Stanley Asia (Singapore) picked up 14.09 lakh shares (0.1 percent stake) in the company at Rs 257.5 per share for Rs 36.28 crore from UBS AG.

<img class="alignnone size-full wp-image-13679221 aligncenter" src="https://images.moneycontrol.com/static-mcnews/2025/11/20251116192423_Image3215112025.jpg" alt="Image3215112025" width="1944" height="5228" />

<img class="alignnone size-full wp-image-13679222 aligncenter" src="https://images.moneycontrol.com/static-mcnews/2025/11/20251116192443_Image3315112025.jpg" alt="Image3315112025" width="1944" height="2639" />
<div style="all: initial !important;"></div>

Promoter offloads 16.4% stake in Sagility, 5 global & domestic institutional investors pick 8.6% shares

Netherlands-based promoter Sagility B V has offloaded 16.4 percent equity stake in Sagility that provides technology-enabled business solutions and services to clients in the US healthcare industry, via open market transactions on November 14.

Despite this big stake sale, Sagility shares rallied 5.6 percent to Rs 53.28 with above-average volumes, witnessing a strong breakout after consolidation seen in the past couple of weeks.

Sagility B V sold 76.9 crore equity shares (equivalent to 16.4 percent of paid-up equity) at Rs 47.6 per share, valued at Rs 3,660.44 crore.

As of September 2025, promoter held 67.38 percent stake in Sagility, which now reduced to around 51 percent.

However, global and domestic institutional investors were buyers for some portion of the stake sold by promoter at same price in Sagility. Portfolio management company Unifi Capital and its Unifi Blend Fund 2 were the largest buyer amongst them, acquiring 22.05 crore shares (4.71 percent stake) at same price, valued at Rs 1,049.65 crore.

ICICI Prudential Mutual Fund bought 3.13 crore shares in Sagility for Rs 149.39 crore, while Societe Generale picked up 8.48 crore shares for Rs 403.75 crore.

Further, Norges Bank on account of the Government Pension Fund Global purchased 3.71 crore shares amounting to Rs 176.59 crore, and Morgan Stanley Asia Singapore acquired 2.76 crore shares for Rs 131.47 crore.

Meanwhile, Rain Industries was also in action, falling 2.44 percent to Rs 116.87, and extending downtrend for eighth consecutive session. First Water Fund, owned by First Water Capital Advisors, bought additional 26 lakh shares (0.77 percent stake) in the calcined petroleum coke, coal tar pitch and other specialty chemicals producer at Rs 120 per share for Rs 31.2 crore.

Haresh Tikamdas Kaswani, and K2 Family Private Trust were the sellers in this block deal, offloading 12 lakh shares for Rs 14.4 crore and 14 lakh shares for Rs 16.8 crore, respectively, in Rain Industries.

The brisk action was also seen in Shaily Engineering Plastics, the injection moulded precision plastic components maker, which ended at new closing high of Rs 2,622.8, up 0.47 percent. Promoters - Amit Mahendra Sanghvi, and Laxman Sanghvi sold 1.5 lakh shares (0.32 percent stake) at Rs 2,585.1 per share for Rs 38.77 crore.

Morgan Stanley IFSC Fund, SI Investments Broking, and Motilal Oswal MF picked the said 0.32 percent stake in Shaily from promoters.

The small block deal was also seen in Pine Labs, the fintech company, which surged 13.52 percent to Rs 250.89 on its market debut today. Morgan Stanley Asia (Singapore) picked up 14.09 lakh shares (0.1 percent stake) in the company at Rs 257.5 per share for Rs 36.28 crore from UBS AG.

Promoter offloads 16.4% stake in Sagility, 5 global &amp; domestic institutional investors pick 8.6% shares

Kotak Mahindra Bank on Friday said its board will meet next week to consider a proposal for a stock split.

In a filing to the stock exchanges, the bank said a meedting of the Board of Directors will convene on November 21, 2025, to consider, among other matters, the sub-division of its equity shares with a face value of Rs 5 each, fully paid-up.

The manner of the proposed split will be decided by the board, the company said.

<a href="https://www.moneycontrol.com/news/business/kotak-mahindra-bank-pat-falls-2-7-yoy-to-rs-3-253-crore-in-q2fy26-13631944.html" target="_blank">The private lender reported </a>a 2.7 percent year-on-year fall in its standalone net profit to Rs 3,253 crore in the second quarter of the current financial year. In a year ago period, net profit stood at Rs 3,344 crore.

Net Interest Income (NII) for Q2FY26 increased to Rs 7,311 crore, up 4 percent YoY from Rs 7,020 crore in Q2FY25. Net Interest Margin (NIM) was 4.54 percent for Q2FY26. Cost of funds was 4.70 percent for Q2FY26.

Net Advances increased 16 percent YoY to Rs 462,688 crore as at September 30, 2025 from Rs 399,522 crore as at September 30, 2024.

Shares of <a href="https://www.moneycontrol.com/india/stockpricequote/banks-private-sector/kotakmahindrabank/KMB">Kotak Mahindra Bank</a> ended marginally higher on the NSE at Rs 2,082.80, up 0.37 per cent.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

A financial journalist with over 10 years of experience, specialising in tracking stock market movements and fundamental developments that impact investors and the broader economy. A keen observer of global financial markets, I regularly engage with leading market voices to write stories. At Moneycontrol, I focus on decoding market trends, policy shifts and economic changes, driven by a constant passion to learn, analyse, and share knowledge with my readers.

Kotak Mahindra Bank board to consider stock split next week

Kotak Mahindra Bank on Friday said its board will meet next week to consider a proposal for a stock split.

In a filing to the stock exchanges, the bank said a meedting of the Board of Directors will convene on November 21, 2025, to consider, among other matters, the sub-division of its equity shares with a face value of Rs 5 each, fully paid-up.

The manner of the proposed split will be decided by the board, the company said.

The private lender reported a 2.7 percent year-on-year fall in its standalone net profit to Rs 3,253 crore in the second quarter of the current financial year. In a year ago period, net profit stood at Rs 3,344 crore.

Net Interest Income (NII) for Q2FY26 increased to Rs 7,311 crore, up 4 percent YoY from Rs 7,020 crore in Q2FY25. Net Interest Margin (NIM) was 4.54 percent for Q2FY26. Cost of funds was 4.70 percent for Q2FY26.

Net Advances increased 16 percent YoY to Rs 462,688 crore as at September 30, 2025 from Rs 399,522 crore as at September 30, 2024.

Shares of Kotak Mahindra Bank ended marginally higher on the NSE at Rs 2,082.80, up 0.37 per cent.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

Auto Ancillaries - Sheet Metals Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Auto Ancillaries - Sheet Metals industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q2 FY25-26

Stock News

IRB Infrastructure share price in focus after arm bags project of Rs 9,270 crore

Alembic Pharma shares in focus on USFDA nod for Diltiazem Hydrochloride tablets

Stocks to Watch Today: Lupin, Narayana Hrudayala, V2 Retail, Websol, TruAlt Bioenergy, IRB Infra, Alembic Pharma, Max Healthcare in focus on 17 November

Promoter offloads 16.4% stake in Sagility, 5 global & domestic institutional investors pick 8.6% shares

Kotak Mahindra Bank board to consider stock split next week

Auto Ancillaries - Sheet Metals Industry StocksCheck latest stock performance, list of stocks, earnings review & more details about the Auto Ancillaries - Sheet Metals industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q2 FY25-26

Stock News

IRB Infrastructure share price in focus after arm bags project of Rs 9,270 crore

Alembic Pharma shares in focus on USFDA nod for Diltiazem Hydrochloride tablets

Stocks to Watch Today: Lupin, Narayana Hrudayala, V2 Retail, Websol, TruAlt Bioenergy, IRB Infra, Alembic Pharma, Max Healthcare in focus on 17 November

Promoter offloads 16.4% stake in Sagility, 5 global &amp; domestic institutional investors pick 8.6% shares

Kotak Mahindra Bank board to consider stock split next week

Auto Ancillaries - Sheet Metals Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Auto Ancillaries - Sheet Metals industry stocks.

Promoter offloads 16.4% stake in Sagility, 5 global & domestic institutional investors pick 8.6% shares